Depreciation of Acrivon Therapeutics, Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Acrivon Therapeutics, Inc. quarterly and annual Depreciation in USD history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • Acrivon Therapeutics, Inc. Depreciation for the quarter ending 30 Sep 2025 was $300,000, unchanged year-over-year.
  • Acrivon Therapeutics, Inc. Depreciation for the twelve months ending 30 Sep 2025 was $1,193,000, a 28% increase year-over-year.
  • Acrivon Therapeutics, Inc. annual Depreciation for 2024 was $1,006,000, a 88% increase from 2023.
  • Acrivon Therapeutics, Inc. annual Depreciation for 2023 was $536,000, a 47% increase from 2022.
  • Acrivon Therapeutics, Inc. annual Depreciation for 2022 was $364,000, a 884% increase from 2021.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Acrivon Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,193,000 $300,000 $0 0% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $1,193,000 $300,000 +$100,000 +50% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $1,093,000 $311,000 +$87,000 +39% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $1,006,000 $282,000 +$71,000 +34% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $935,000 $300,000 +$200,000 +200% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $735,000 $200,000 +$100,000 +100% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $635,000 $224,000 +$99,000 +79% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $536,000 $211,000 +$92,000 +77% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $444,000 $100,000 $0 0% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $444,000 $100,000 $0 0% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $444,000 $125,000 +$80,000 +178% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $364,000 $119,000 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $100,000 +$91,000 +1011% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $100,000 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $45,000 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q3 2021 $9,000 01 Jul 2021 30 Sep 2021 10-Q 15 Dec 2022 2022 Q3

Acrivon Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,006,000 +$470,000 +88% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $536,000 +$172,000 +47% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $364,000 +$327,000 +884% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $37,000 01 Jan 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.